• metastatic/advanced OC (mOC) - 2nd line (L2) 3

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• avelumab based treatment
• avelumab alone
• avelumab plus pegylated liposomal doxorubicin
• Immune checkpoint association
• nivolumab plus ipilimumab